The Role of Adjuvant Therapy in the Management of Chronic Urticaria

Actas Dermosifiliogr. 2023 Jun;114(6):T523-T530. doi: 10.1016/j.ad.2023.05.008. Epub 2023 May 10.
[Article in English, Spanish]

Abstract

Recent guideline on the management of urticaria recommends second-generation H1-antihistamine as the first-line therapy, with dose increases of up to fourfold if inadequately controlled. However, the treatment of chronic spontaneous urticaria (CSU) is often disappointing, so additional adjuvant therapies are needed to increase the effectiveness of first-line therapy, especially in patients who are refractory to the increase of antihistamine doses. Recent studies recommend various adjuvant therapy modalities for CSU, such as biological agents, immunosuppressants, leukotriene receptor antagonists, H2-antihistamine, sulfones, autologous serum therapy, phototherapy, vitaminD, antioxidants, and probiotics. This literature review was made to determine the effectiveness of various adjuvant therapies in managing CSU.

Keywords: Adjuvant therapy; Chronic spontaneous urticaria; Complementary therapy; Terapia adyuvante; Terapia complementaria; Urticaria crónica espontánea.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Chronic Urticaria* / chemically induced
  • Chronic Urticaria* / drug therapy
  • Combined Modality Therapy
  • Histamine H1 Antagonists / therapeutic use
  • Humans
  • Omalizumab / therapeutic use
  • Urticaria* / drug therapy

Substances

  • Histamine H1 Antagonists
  • Omalizumab